AI becomes central to breast cancer care

A company based in the Netherlands has raised $16 million to augment its Transpara Breast AI tool. ScreenPoint Medical’s new funding comes less than a year after the FDA approved the first AI-powered platform (Clairity Breast) to predict a woman’s risk of developing breast cancer over the next five years using only a standard mammogram. The Breast Cancer Research Foundation notes that more than 2.3 million women worldwide are diagnosed with breast cancer each year, including more than 370,000 in the United States. ScreenPoint says research shows Transpara, which is used in more than 30 million countries and has processed 12 million mammograms, has had “significant impact” on both cancer detection and workload reduction.